Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2016

Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2016
Published Oct 12, 2016
42 pages — Published Oct 12, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2016, provides in depth analysis on Cathepsin S (CTSS or EC 3.4.22.27) targeted pipeline therapeutics.

The report provides comprehensive information on the Cathepsin S (CTSS or EC 3.4.22.27), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cathepsin S (CTSS or EC 3.4.22.27)
- The report reviews Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cathepsin S (CTSS or EC 3.4.22.27)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demograph

  
Source:
Document ID
GMDHC0582TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Cathepsin S (CTSS or EC 3.4.22.27) Overview61
Therapeutics Development73
  Cathepsin S (CTSS or EC 3.4.22.27) Products under Development by Stage of Development71
  Cathepsin S (CTSS or EC 3.4.22.27) Products under Development by Therapy Area81
  Cathepsin S (CTSS or EC 3.4.22.27) Products under Development by Indication91
Cathepsin S (CTSS or EC 3.4.22.27) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
Cathepsin S (CTSS or EC 3.4.22.27) Products under Development by Companies122
Cathepsin S (CTSS or EC 3.4.22.27) Therapeutics Assessment145
  Assessment by Monotherapy/Combination Products141
  Assessment by Mechanism of Action151
  Assessment by Route of Administration161
  Assessment by Molecule Type172
Cathepsin S (CTSS or EC 3.4.22.27) Companies Involved in Therapeutics Development195
  Amura Holdings Limited191
  F. Hoffmann-La Roche Ltd.201
  Fusion Antibodies Limited211
  Sanofi221
  Virobay Inc.231
Cathepsin S (CTSS or EC 3.4.22.27) Drug Profiles2412
  AM-3840 Drug Profile241
  AM-3876 Drug Profile251
  Fsn-0503h Drug Profile261
  RG-7625 Drug Profile271
  RO-5461111 Drug Profile281
  SAR-114137 Drug Profile291
  VBY-036 Drug Profile302
  VBY-129 Drug Profile321
  VBY-285 Drug Profile331
  VBY-50365 Drug Profile341
  VBY-825 Drug Profile351
Cathepsin S (CTSS or EC 3.4.22.27) Dormant Projects361
Cathepsin S (CTSS or EC 3.4.22.27) Discontinued Products371
Cathepsin S (CTSS or EC 3.4.22.27) Featured News &Press Releases383
  Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease381
  Nov 14, 2014: Virobay To Present Data On Two Cathepsin S Inhibitor Programs In Neuropathic Pain And Alzheimer's Disease At The 2014 Society For Neuroscience Annual Meeting381
  May 23, 2013: Virobay Initiates Phase I Trial Of VBY-036 For Treatment Of Neuropathic Pain391
  Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model392
Appendix412
  Methodology411
  Coverage411
  Secondary Research411
  Primary Research411
  Expert Panel Validation411
  Contact Us411
  Disclaimer421

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2016" Oct 12, 2016. Alacra Store. May 05, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Cathepsin-S-CTSS-or-EC-3-4-22-27-Pipeline-Review-H2-2016-2088-16801>
  
APA:
Global Markets Direct - Market Research. (2016). Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2016 Oct 12, 2016. New York, NY: Alacra Store. Retrieved May 05, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Cathepsin-S-CTSS-or-EC-3-4-22-27-Pipeline-Review-H2-2016-2088-16801>
  
US$ 3,500.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.